{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:54:12Z","timestamp":1769597652845,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11916-024-01259-x","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:01:55Z","timestamp":1714392115000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long\u2013Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine"],"prefix":"10.1007","volume":"28","author":[{"given":"Soohyun","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung\u2013Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"5","key":"1259_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1259_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563\u201378.","journal-title":"Cephalalgia"},{"issue":"5","key":"1259_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"J Natoli","year":"2010","unstructured":"Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599\u2013609.","journal-title":"Cephalalgia"},{"issue":"5 Supplement 1","key":"1259_CR4","first-page":"S3","volume":"72","author":"RB Lipton","year":"2009","unstructured":"Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(5 Supplement 1):S3\u20137.","journal-title":"Neurology"},{"issue":"5","key":"1259_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"issue":"2","key":"1259_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab versus topiramate for the prevention of migraine\u2013a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108\u201318.","journal-title":"Cephalalgia"},{"issue":"7","key":"1259_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.neurol.2021.07.006","volume":"177","author":"A Ducros","year":"2021","unstructured":"Ducros A, de Gaalon S, Roos C, Donnet A, Giraud P, Gu\u00e9gan-Massardier E, et al. Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment. Revue neurologique. 2021;177(7):734\u201352.","journal-title":"Revue neurologique"},{"issue":"1","key":"1259_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-14-1","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care. J Headache Pain. 2019;20(1):1\u201352.","journal-title":"J Headache Pain"},{"issue":"5","key":"1259_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"issue":"10","key":"1259_CR10","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/head.13653","volume":"59","author":"JF Rothrock","year":"2019","unstructured":"Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, et al. FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache: The Journal of Head and Face Pain. 2019;59(10):1700\u201313.","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"1","key":"1259_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):1\u201310.","journal-title":"J Headache Pain"},{"issue":"1","key":"1259_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-020-00057-1","volume":"2","author":"H-C Diener","year":"2020","unstructured":"Diener H-C, F\u00f6rderreuther S, Gaul C, Giese F, Hamann T, Holle-Lee D, et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Neurological research and practice. 2020;2(1):1\u20136.","journal-title":"Neurological research and practice"},{"issue":"1","key":"1259_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01228-4","volume":"22","author":"HW Schytz","year":"2021","unstructured":"Schytz HW, Amin FM, Jensen RH, Carlsen L, Maarbjerg S, Lund N, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain Danish Headache Society, 2020. J Headache Pain. 2021;22(1):1\u201331.","journal-title":"J Headache Pain"},{"issue":"6","key":"1259_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.5114\/aoms\/153955","volume":"18","author":"I Domitrz","year":"2022","unstructured":"Domitrz I, Kozubski W, Ro\u017cniecki JJ, St\u0119pie\u0144 A, Boczarska-Jedynak M. The Polish Headache Society and the Headache Section of the Polish Neurological Society Consensus Statement: update on new pharmacological therapies for migraine in clinical practice and public medication reimbursement program for chronic migraine. Archives of Medical Science: AMS. 2022;18(6):1705.","journal-title":"Archives of Medical Science: AMS"},{"issue":"7","key":"1259_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Society BoDotAH. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain. 2021;61(7):1021\u201339.","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"1","key":"1259_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20132022 update. J Headache Pain. 2022;23(1):1\u201319.","journal-title":"J Headache Pain"},{"issue":"6","key":"1259_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s40120-023-00550-0","volume":"12","author":"T Alsaadi","year":"2023","unstructured":"Alsaadi T, Kayed DM, Al-Madani A, Hassan AM, Terruzzi A, Krieger D, et al. Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE. Neurology and Therapy. 2023;12(6):1845\u201365.","journal-title":"Neurology and Therapy"},{"issue":"1","key":"1259_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-018-0948-x","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D-D, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):1\u201333.","journal-title":"J Headache Pain"},{"issue":"5","key":"1259_CR19","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716\u201325.","journal-title":"Eur J Neurol"},{"issue":"10","key":"1259_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11916-023-01167-6","volume":"27","author":"S Cho","year":"2023","unstructured":"Cho S, Kim B-K. Update of Gepants in the Treatment of Chronic Migraine. Curr Pain Headache Rep. 2023;27(10):561\u20139.","journal-title":"Curr Pain Headache Rep"},{"key":"1259_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1018-8","volume":"20","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019;20:1\u20135 Real world study for the course of migraine after the discontinuation of CGRP mAbs in pateints with CM.","journal-title":"J Headache Pain"},{"key":"1259_CR22","doi-asserted-by":"publisher","unstructured":"\u2022\u00a0De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021;42(8):3297\u2013303. https:\/\/doi.org\/10.1007\/s10072-020-05022-z. Epub 2021 Jan 2. PMID: 33389227.\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/33389227\/","DOI":"10.1007\/s10072-020-05022-z"},{"issue":"11\u201312","key":"1259_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"\u2022 Gantenbein AR, Agosti R, Gobbi C, Fl\u00fcgel D, Schankin CJ, Viceic D, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2013a real-life cohort study. Cephalalgia. 2021;41(11\u201312):1181\u20136. Real world study for the course of migraine after the discontinuation and restart of CGRP mAbs in pateints with EM and CM.","journal-title":"Cephalalgia"},{"issue":"1","key":"1259_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):1\u201310 Real world study for the course of migraine after the discontinuation of CGRP mAbs in pateints with HFEM and CM.","journal-title":"J Headache Pain"},{"issue":"1","key":"1259_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"\u2022 Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP (\u2212 receptor) antibodies. The Journal of Headache and Pain. 2021;22(1):1\u20139. Real world study for the course of migraine after the discontinuation of CGRP mAbs in pateints with EM and CM.","journal-title":"The Journal of Headache and Pain"},{"issue":"5","key":"1259_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"\u2022 Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022;29(5):1505\u201313. Real world study for the course of migraine after the discontinuation and restart of CGRP mAbs in pateints with CM.","journal-title":"Eur J Neurol"},{"issue":"4\u20135","key":"1259_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"\u2022\u2022 Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, et al. Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2022;42(4\u20135):326\u201334. Real world study for the course of migraine after the discontinuation of CGRP mAbs in pateints with EM and CM.","journal-title":"Cephalalgia."},{"issue":"7","key":"1259_CR28","doi-asserted-by":"publisher","first-page":"e2662","DOI":"10.1002\/brb3.2662","volume":"12","author":"M Nsaka","year":"2022","unstructured":"\u2022 Nsaka M, Scheffler A, Wurthmann S, Schenk H, Kleinschnitz C, Glas M, et al. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Brain and Behavior. 2022;12(7):e2662.\u00a0Real world study for the course of migraine after the discontinuation of CGRP mAbs in pateints with EM and CM.","journal-title":"Brain and Behavior."},{"issue":"1","key":"1259_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01417-9","volume":"23","author":"B Raffaelli","year":"2022","unstructured":"\u2022 Raffaelli B, Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, et al. Resumption of migraine preventive treatment with CGRP (-receptor) antibodies after a 3-month drug holiday: a real-world experience. The Journal of Headache and Pain. 2022;23(1):1\u20138. Real world study for the outecome of retreatment with CGRP mAbs after the discontinuation in patients with EM and CM.","journal-title":"The Journal of Headache and Pain"},{"issue":"11","key":"1259_CR30","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s00415-023-11872-2","volume":"270","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Guerzoni S, Iannone LF, Baraldi C, Rao R, et al. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: The multicenter prospective cohort RE-DO study. J Neurol. 2023;270(11):5436\u201348 Real world study for the outecome of retreatment with CGRP mAbs after the discontinuation in patients with HFEM and CM.","journal-title":"J Neurol"},{"issue":"5","key":"1259_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cpt.799","volume":"103","author":"J de Hoon","year":"2018","unstructured":"de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103(5):815\u201325.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1259_CR32","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1111\/bcp.14096","volume":"85","author":"JB Fiedler-Kelly","year":"2019","unstructured":"Fiedler-Kelly JB, Cohen-Barak O, Morris DN, Ludwig E, Rasamoelisolo M, Shen H, et al. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br J Clin Pharmacol. 2019;85(12):2721\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1259_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jcph.1511","volume":"60","author":"W Kielbasa","year":"2020","unstructured":"Kielbasa W, Quinlan T. Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol. 2020;60(2):229\u201339.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1259_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"\u2022 Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK. Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache: The Journal of Head and Face Pain. 2019;59(6):834\u201347. Subgroup analysis of RCTs (EVOLVE-1 and EVOLVE-2) for the course of migraine after the discontinuation of CGRP mAbs in pateints with EM.","journal-title":"Headache: The Journal of Head and Face Pain."},{"key":"1259_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1009-9","volume":"20","author":"P Martelletti","year":"2019","unstructured":"Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting calcitonin-gene-related-peptide with the disease-modifying migraine drugs (DMMDs). J Headache Pain. 2019;20:1\u20133.","journal-title":"J Headache Pain"},{"issue":"8","key":"1259_CR36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1526-4610.2011.01986.x","volume":"51","author":"EW Loder","year":"2011","unstructured":"Loder EW, Rizzoli P. Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache: The Journal of Head and Face Pain. 2011;51(8):1336\u201345.","journal-title":"Headache: The Journal of Head and Face Pain."},{"issue":"1","key":"1259_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102420973994","volume":"41","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021;41(1):6\u201316.","journal-title":"Cephalalgia"},{"issue":"11\u201312","key":"1259_CR38","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1177\/03331024211010308","volume":"41","author":"H-C Diener","year":"2021","unstructured":"Diener H-C, Ashina M, Ritter S, Paiva Da Silva Lima G, Rasmussen S, Zielman R, et al. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. Cephalalgia. 2021;41(11\u201312):1262\u20137.","journal-title":"Cephalalgia."},{"issue":"8","key":"1259_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1212\/WNL.0b013e31820d8af2","volume":"76","author":"A Manack","year":"2011","unstructured":"Manack A, Buse D, Serrano D, Turkel C, Lipton R. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711\u20138.","journal-title":"Neurology"},{"key":"1259_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WF, Adams AM, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:1\u201312.","journal-title":"J Headache Pain"},{"key":"1259_CR41","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1111\/j.1526-4610.2006.00602.x","volume":"46","author":"D Dodick","year":"2006","unstructured":"Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache: The Journal of Head and Face Pain. 2006;46:S182\u201391.","journal-title":"Headache: The Journal of Head and Face Pain."},{"issue":"8","key":"1259_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455\u201364.","journal-title":"Nat Rev Neurol"},{"key":"1259_CR43","unstructured":"Sur C, Hargreaves R, Bell I, Dancho M, Graham S, Hostetler E, Kane S, Kim J, Michener M, Miller P, O\u2019Malley S, Salvatore C, Selnick H, Staas D, Stump C, Williams D, Wood M, Zeng Z, Cook J. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia. 2009;29(Suppl 1):136\u20137.\nhttps:\/\/scholar.google.com\/scholar_lookup? journal=Cephalalgia&title=CSF+levels+and+binding+pattern+of+novel+CGRP+receptor+antagonists+in+rhesus+monkey+and+human+central+nervous+system:+toward+the+development+of+a+PET+tracer&author=C+Sur&author=R+Hargreaves&author=I+Bell&author=M+Dancho&author=S+Graham&volume=29&issue=Suppl+1&publication_year=2009&pages=136-7&"},{"issue":"6","key":"1259_CR44","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/head.13510","volume":"59","author":"R Hargreaves","year":"2019","unstructured":"Hargreaves R, Olesen J. Calcitonin gene-related peptide modulators\u2013The history and renaissance of a new migraine drug class. Headache: The Journal of Head and Face Pain. 2019;59(6):951\u201370.","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"2","key":"1259_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1259_CR46","doi-asserted-by":"publisher","unstructured":"Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d'Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S; Italian Migraine Registry (I-GRAINE) study group. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I- GRAINE study. J Neurol. 2024. https:\/\/doi.org\/10.1007\/s00415-024-12192-9. Epub ahead of print. PMID: 38342785.\nhttps:\/\/pubmed.ncbi.nlm.nih.gov\/38342785\/","DOI":"10.1007\/s00415-024-12192-9"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-024-01259-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:25:40Z","timestamp":1721892340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-024-01259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s11916-024-01259-x","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"12 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Soohyun Cho received honoraria as a speaker from\u00a0Celltrion Pharm, Daewoong Pharm, Boryung, Whan In Pharm, Teva and SK Pharm. He has been the principal investigator of clinical trials sponsored by Teva and SK Pharm. Byung\u2013Kun Kim served on Lundbeck\u2019s Advisory Board. He received honoraria as a moderator and speaker from\u00a0Lundbeck, AbbVie, Pfizer, Eli Lilly, Teva, Yuyu Pharm, and SK Pharm. He has been the principal investigator of clinical trials sponsored by Eli\u2013Lilly, Novartis, Lundbeck, Teva, AbbVie, and Ildong Pharm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}